Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.11.2010 | Brief Report

DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast

verfasst von: Katie T. Huang, Alexander Dobrovic, Max Yan, Rooshdiya Z. Karim, C. Soon Lee, Sunil R. Lakhani, Stephen B. Fox

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Phyllodes tumours and cellular fibroadenomas are both fibroepithelial tumours of the breast. Phyllodes tumours, unlike fibroadenomas, have the ability to recur and metastasise. Although these lesions can be distinguished by their stromal cellularity, mitotic index, presence or absence of stromal overgrowth and cellular atypia, there is overlap and not infrequently a definitive diagnosis cannot be made, particularly on biopsy. We sought to evaluate whether DNA promoter methylation profiling using selected genes known to be methylated in cancer would allow us to learn more about the biology of these tumours, and whether it could identify methylation markers that could differentiate phyllodes tumours from fibroadenomas and/or distinguish phyllodes tumours of different grades. Methylation-sensitive high resolution melting (MS-HRM) was used to screen promoter DNA methylation changes in 86 phyllodes tumours (15 benign, 28 borderline, 43 malignant) and 26 fibroadenomas. A panel of 11 genes (RASSF1A, TWIST1, APC, WIF1, MGMT, MAL, RARβ, CDKN2A, CDH1, TP73 and MLH1) was tested. Methylation status was correlated with histology and with clinicopathological parameters. Five of the gene promoters showed some methylation in a proportion of phyllodes tumours; RASSF1A, 45.3%; TWIST1, 10.7%; APC, 4.1%; WIF1, 2.9% and MGMT, 1.3%. Only two genes showed any methylation in fibroadenomas usually at background levels; RASSF1A, 53.8% and MGMT, 8.3%. No CDKN2A methylation was observed in either tumour type, contrary to previous reports. Overall, the methylation patterns differed little from that which might be seen in normal cells. However, significant levels of methylation of RASSF1A (24.4%) and TWIST1 (7.1%) was observed in some phyllodes tumours. Elevated RASSF1A and/or TWIST1 methylation was significantly associated with phyllodes tumours compared with fibroadenomas (P = 0.02), TWIST1 methylation correlated with increasing malignancy in phyllodes tumours (P < 0.001). In conclusion, assessment of methylation of RASSF1A and TWIST1 may aid in the diagnosis of phyllodes tumours. The absence of frequent methylation in fibroadenomas supports a non-neoplastic origin.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat McKenna AM, Pintilie M, Youngson B, Done SJ (2007) Quantification of the morphologic features of fibroepithelial tumors of the breast. Arch Pathol Lab Med 131(10):1568–1573PubMed McKenna AM, Pintilie M, Youngson B, Done SJ (2007) Quantification of the morphologic features of fibroepithelial tumors of the breast. Arch Pathol Lab Med 131(10):1568–1573PubMed
2.
Zurück zum Zitat Guerrero MA, Ballard BR, Grau AM (2003) Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol 12(1):27–37CrossRefPubMed Guerrero MA, Ballard BR, Grau AM (2003) Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol 12(1):27–37CrossRefPubMed
3.
Zurück zum Zitat Karim RZ, Scolyer RA, Tse GM, Tan PH, Putti TC, Lee CS (2009) Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. Pathology 41(2):105–117CrossRefPubMed Karim RZ, Scolyer RA, Tse GM, Tan PH, Putti TC, Lee CS (2009) Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. Pathology 41(2):105–117CrossRefPubMed
4.
Zurück zum Zitat Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS (2009) Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. Breast 18(3):165–170CrossRefPubMed Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS (2009) Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. Breast 18(3):165–170CrossRefPubMed
5.
Zurück zum Zitat Jacklin RK, Ridgway PF, Ziprin P, Healy V, Hadjiminas D, Darzi A (2006) Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol 59(5):454–459CrossRefPubMed Jacklin RK, Ridgway PF, Ziprin P, Healy V, Hadjiminas D, Darzi A (2006) Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol 59(5):454–459CrossRefPubMed
6.
Zurück zum Zitat Krishnamurthy S, Ashfaq R, Shin HJ, Sneige N (2000) Distinction of phyllodes tumor from fibroadenoma: a reappraisal of an old problem. Cancer 90(6):342–349CrossRefPubMed Krishnamurthy S, Ashfaq R, Shin HJ, Sneige N (2000) Distinction of phyllodes tumor from fibroadenoma: a reappraisal of an old problem. Cancer 90(6):342–349CrossRefPubMed
7.
Zurück zum Zitat Esteller M (2008) Molecular origins of cancer: epigenetics in cancer. N Engl J Med 358(11):1148–1159CrossRefPubMed Esteller M (2008) Molecular origins of cancer: epigenetics in cancer. N Engl J Med 358(11):1148–1159CrossRefPubMed
8.
Zurück zum Zitat Herman JG, Baylin SB (2003) Mechanisms of disease: gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054CrossRefPubMed Herman JG, Baylin SB (2003) Mechanisms of disease: gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054CrossRefPubMed
9.
Zurück zum Zitat Levenson VV (2007) Biomarkers for early detection of breast cancer: what, when, and where? Biochim Biophys Acta 1770(6):847–856PubMed Levenson VV (2007) Biomarkers for early detection of breast cancer: what, when, and where? Biochim Biophys Acta 1770(6):847–856PubMed
10.
Zurück zum Zitat House MG, Guo M, Efron DT, Lillemoe KD, Cameron JL, Syphard JE, Hooker CM, Abraham SC, Montgomery EA, Herman JG, Brock MV (2003) Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 7(8):1004–1014 discussion 1014CrossRefPubMed House MG, Guo M, Efron DT, Lillemoe KD, Cameron JL, Syphard JE, Hooker CM, Abraham SC, Montgomery EA, Herman JG, Brock MV (2003) Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 7(8):1004–1014 discussion 1014CrossRefPubMed
11.
Zurück zum Zitat Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M (2006) DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19(1):106–114CrossRefPubMed Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M (2006) DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19(1):106–114CrossRefPubMed
12.
Zurück zum Zitat Saito K, Sakurai S, Sano T, Sakamoto K, Asao T, Hosoya Y, Nakajima T, Kuwano H (2008) Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy. Cancer Sci 99(2):253–259CrossRefPubMed Saito K, Sakurai S, Sano T, Sakamoto K, Asao T, Hosoya Y, Nakajima T, Kuwano H (2008) Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy. Cancer Sci 99(2):253–259CrossRefPubMed
13.
Zurück zum Zitat Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H, Dammann R (2005) Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114(3):442–447CrossRefPubMed Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H, Dammann R (2005) Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114(3):442–447CrossRefPubMed
14.
Zurück zum Zitat McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235CrossRefPubMed McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235CrossRefPubMed
15.
Zurück zum Zitat Kristensen LS, Mikeska T, Krypuy M, Dobrovic A (2008) Sensitive melting analysis after real time-methylation specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 36(7):e42CrossRefPubMed Kristensen LS, Mikeska T, Krypuy M, Dobrovic A (2008) Sensitive melting analysis after real time-methylation specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 36(7):e42CrossRefPubMed
16.
Zurück zum Zitat Wojdacz TK, Dobrovic A (2007) Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35(6):e41CrossRefPubMed Wojdacz TK, Dobrovic A (2007) Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35(6):e41CrossRefPubMed
17.
Zurück zum Zitat Candiloro IL, Mikeska T, Hokland P, Dobrovic A (2008) Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin 1(1):7 Candiloro IL, Mikeska T, Hokland P, Dobrovic A (2008) Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin 1(1):7
18.
Zurück zum Zitat Wojdacz T, Hansen L, Dobrovic A (2008) A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes 1(1):54CrossRefPubMed Wojdacz T, Hansen L, Dobrovic A (2008) A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes 1(1):54CrossRefPubMed
19.
Zurück zum Zitat Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63(5):1114–1121PubMed Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63(5):1114–1121PubMed
20.
Zurück zum Zitat Candiloro IL, Dobrovic A (2009) Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila Pa) 2(10):862–867 Candiloro IL, Dobrovic A (2009) Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila Pa) 2(10):862–867
21.
Zurück zum Zitat Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61(8):3225–3229PubMed Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61(8):3225–3229PubMed
22.
Zurück zum Zitat Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57CrossRefPubMed Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57CrossRefPubMed
23.
Zurück zum Zitat Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T, Oka M (2009) Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 125(2):388–397CrossRefPubMed Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T, Oka M (2009) Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 125(2):388–397CrossRefPubMed
24.
Zurück zum Zitat Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68(1):1–11CrossRefPubMed Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68(1):1–11CrossRefPubMed
25.
Zurück zum Zitat Kim JH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Park MH, Yoon JH (2009) Borderline and malignant phyllodes tumors display similar promoter methylation profiles. Virchows Arch 455(6):469–475CrossRefPubMed Kim JH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Park MH, Yoon JH (2009) Borderline and malignant phyllodes tumors display similar promoter methylation profiles. Virchows Arch 455(6):469–475CrossRefPubMed
26.
Zurück zum Zitat Harvey K, Tapon N (2007) The Salvador–Warts–Hippo pathway—an emerging tumour-suppressor network. Nat Rev Cancer 7(3):182–191CrossRefPubMed Harvey K, Tapon N (2007) The Salvador–Warts–Hippo pathway—an emerging tumour-suppressor network. Nat Rev Cancer 7(3):182–191CrossRefPubMed
28.
Zurück zum Zitat Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA (2002) The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22(12):4309–4318CrossRefPubMed Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA (2002) The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22(12):4309–4318CrossRefPubMed
29.
Zurück zum Zitat Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC (2006) Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 66(5):2785–2793CrossRefPubMed Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC (2006) Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 66(5):2785–2793CrossRefPubMed
30.
Zurück zum Zitat Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, Im CR, Lee JO, Yonehara S, Lim DS (2006) Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 66(5):2562–2569CrossRefPubMed Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, Im CR, Lee JO, Yonehara S, Lim DS (2006) Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 66(5):2562–2569CrossRefPubMed
31.
Zurück zum Zitat Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, Liu JC, Huang TH (2003) Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 63(19):6178–6186PubMed Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, Liu JC, Huang TH (2003) Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 63(19):6178–6186PubMed
32.
Zurück zum Zitat Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540CrossRefPubMed Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540CrossRefPubMed
33.
34.
Zurück zum Zitat Peters I, Vaske B, Albrecht K, Kuczyk MA, Jonas U, Serth J (2007) Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev 16(12):2526–2532CrossRefPubMed Peters I, Vaske B, Albrecht K, Kuczyk MA, Jonas U, Serth J (2007) Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev 16(12):2526–2532CrossRefPubMed
35.
Zurück zum Zitat Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA (1999) TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 75(4):566–577CrossRefPubMed Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA (1999) TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 75(4):566–577CrossRefPubMed
36.
Zurück zum Zitat Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13(17):2207–2217CrossRefPubMed Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13(17):2207–2217CrossRefPubMed
37.
Zurück zum Zitat Gort EH, Suijkerbuijk KP, Roothaan SM, Raman V, Vooijs M, van der Wall E, van Diest PJ (2008) Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev 17(12):3325–3330CrossRefPubMed Gort EH, Suijkerbuijk KP, Roothaan SM, Raman V, Vooijs M, van der Wall E, van Diest PJ (2008) Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev 17(12):3325–3330CrossRefPubMed
38.
Zurück zum Zitat Mangi AA, Smith BL, Gadd MA, Tanabe KK, Ott MJ, Souba WW (1999) Surgical management of phyllodes tumors. Arch Surg 134(5):487–492 discussion 492–483CrossRefPubMed Mangi AA, Smith BL, Gadd MA, Tanabe KK, Ott MJ, Souba WW (1999) Surgical management of phyllodes tumors. Arch Surg 134(5):487–492 discussion 492–483CrossRefPubMed
39.
Zurück zum Zitat Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H (1995) Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer 76(10):1779–1785CrossRefPubMed Noguchi S, Yokouchi H, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H (1995) Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. Cancer 76(10):1779–1785CrossRefPubMed
40.
Zurück zum Zitat Klarmann GJ, Decker A, Farrar WL (2008) Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 3(2):59–63CrossRefPubMed Klarmann GJ, Decker A, Farrar WL (2008) Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 3(2):59–63CrossRefPubMed
41.
Zurück zum Zitat Brown AM (2001) Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 3(6):351–355CrossRefPubMed Brown AM (2001) Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 3(6):351–355CrossRefPubMed
42.
Zurück zum Zitat Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, Lakhani SR, Ellis IO, Ellis P, Tomlinson IP (2002) The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 196(4):437–444CrossRefPubMed Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulsom R, Lakhani SR, Ellis IO, Ellis P, Tomlinson IP (2002) The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol 196(4):437–444CrossRefPubMed
43.
Zurück zum Zitat Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T (2008) Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98(6):1147–1156CrossRefPubMed Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T (2008) Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98(6):1147–1156CrossRefPubMed
44.
Zurück zum Zitat Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27(7):1341–1348CrossRefPubMed Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27(7):1341–1348CrossRefPubMed
45.
Zurück zum Zitat Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53):7946–7952CrossRefPubMed Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53):7946–7952CrossRefPubMed
46.
Zurück zum Zitat Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64(14):4717–4720CrossRefPubMed Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64(14):4717–4720CrossRefPubMed
47.
Zurück zum Zitat Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119(4):837–851CrossRefPubMed Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119(4):837–851CrossRefPubMed
48.
Zurück zum Zitat Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59(4):793–797PubMed Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59(4):793–797PubMed
49.
Zurück zum Zitat Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ (2008) A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 214(5):533–544CrossRefPubMed Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ (2008) A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 214(5):533–544CrossRefPubMed
50.
Zurück zum Zitat Di Vinci A, Perdelli L, Banelli B, Salvi S, Casciano I, Gelvi I, Allemanni G, Margallo E, Gatteschi B, Romani M (2005) p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114(3):414–421CrossRefPubMed Di Vinci A, Perdelli L, Banelli B, Salvi S, Casciano I, Gelvi I, Allemanni G, Margallo E, Gatteschi B, Romani M (2005) p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114(3):414–421CrossRefPubMed
Metadaten
Titel
DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast
verfasst von
Katie T. Huang
Alexander Dobrovic
Max Yan
Rooshdiya Z. Karim
C. Soon Lee
Sunil R. Lakhani
Stephen B. Fox
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0970-4

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.